SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 43.46 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 6.49 |
| Book Value / Share | 0.07 |
| Price / Book | n/a |
| NCAV ($M) | 5.28 |
| NCAV / Share | 0.06 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -4.20 |
| Return on Assets (ROA) | -0.91 |
| Return on Equity (ROE) | -1.37 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.21 |
| Current Ratio | 3.21 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 18.49 |
| Assets | 19.70 |
| Liabilities | 13.21 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -34.98 |
| Net Income | -31.71 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -26.97 |
| Cash from Investing | -0.24 |
| Cash from Financing | 6.64 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Anson Funds Management LP | 9.60 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 211,707 | 435,897 | 48.57 | |
| 99,715 | 258,859 | 38.52 | |
| 58,953 | 214,351 | 27.50 | |
| 101,665 | 241,886 | 42.03 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| OCX – OncoCyte Corporation | OKYO – OKYO Pharma Limited |
| ONCO – Onconetix, Inc. | ORGO – Organogenesis Holdings Inc. |
| ORMP – Oramed Pharmaceuticals Inc. |
Financial data and stock pages provided by
Fintel.io